CN107823636A - A kind of medicine for treating tinnitus - Google Patents
A kind of medicine for treating tinnitus Download PDFInfo
- Publication number
- CN107823636A CN107823636A CN201711340568.8A CN201711340568A CN107823636A CN 107823636 A CN107823636 A CN 107823636A CN 201711340568 A CN201711340568 A CN 201711340568A CN 107823636 A CN107823636 A CN 107823636A
- Authority
- CN
- China
- Prior art keywords
- medicine
- injection
- treating tinnitus
- medication
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 208000009205 Tinnitus Diseases 0.000 title claims abstract description 16
- 231100000886 tinnitus Toxicity 0.000 title claims abstract description 16
- 108090000317 Chymotrypsin Proteins 0.000 claims abstract description 6
- 108091005804 Peptidases Proteins 0.000 claims abstract description 6
- 239000004365 Protease Substances 0.000 claims abstract description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 6
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 claims abstract description 6
- 229960002682 cefoxitin Drugs 0.000 claims abstract description 6
- 229960002376 chymotrypsin Drugs 0.000 claims abstract description 6
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229950009041 edaravone Drugs 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 238000001467 acupuncture Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 210000001595 mastoid Anatomy 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 240000007164 Salvia officinalis Species 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 235000005412 red sage Nutrition 0.000 claims description 5
- 229930003451 Vitamin B1 Natural products 0.000 claims description 4
- 230000003444 anaesthetic effect Effects 0.000 claims description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 4
- 229960005205 prednisolone Drugs 0.000 claims description 4
- 229960003495 thiamine Drugs 0.000 claims description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 4
- 239000011691 vitamin B1 Substances 0.000 claims description 4
- 235000010374 vitamin B1 Nutrition 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 206010002091 Anaesthesia Diseases 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 230000037005 anaesthesia Effects 0.000 claims description 2
- 238000001949 anaesthesia Methods 0.000 claims description 2
- 108010048734 sclerotin Proteins 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 230000000840 anti-viral effect Effects 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 210000002569 neuron Anatomy 0.000 abstract description 2
- 230000004792 oxidative damage Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 150000003254 radicals Chemical class 0.000 abstract description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 2
- 208000032625 disorder of ear Diseases 0.000 description 2
- 210000000883 ear external Anatomy 0.000 description 2
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 206010065838 Middle ear inflammation Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 206010033103 otosclerosis Diseases 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21001—Chymotrypsin (3.4.21.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of medicine for treating tinnitus, it is mainly prepared by hydrolysising protease, chymotrypsin, Cefoxitin, Edaravone by certain consumption proportion, medicine of the present invention has Stasis through, the promoting flow of qi and blood circulation, antibacterial, antiviral function, free radical can be removed, suppress vascular endothelial cell, the oxidative damage of nerve cell, treatment tinnitus effect is good, and cure rate is high.
Description
Technical field
The present invention relates to a kind of composition of medicine, especially a kind of medicine for treating tinnitus.
Background technology
Tinnitus is a kind of disease of ear, outer ear disease, otitis externa, impacted cerumen, external ear foreign matter, the acute and chronic of middle ear
Inflammation, the Meniere's syndrome of otospongiosis and inner ear, acoustic neurinoma, can cause tinnitus, be excessively used poisonous to ear
Property effect medicine, as gentamicin, streptomysin or kanamycins also may occur in which tinnitus.Tinnitus can make one to find it hard to concentrate,
The mood alterations such as worry is worried, depression, reach insufferable degree, and more somebody is reported to because seeking medical advice everywhere, bad to control,
There is no easy to handle ruling by law etc., often make patient have a rest owe, feel gloomy and in it is dizzy, brain is swollen, influences work and sleep, make one agitation not
Peace.
The content of the invention
It is an object of the invention to provide a kind of medicine for treating tinnitus, with solve the pain of tinnitus patient,
Another object of the present invention just there is provided the preparation application method of the medicine.
Embodiment
The solution of the present invention includes office's note medication and notes medication again.
First, dosage
1st, the dosage of office's note medication is as follows
Cacaine 2ml, prednisolone 0.1g, vitamin B1 0.1g；
2nd, the dosage for noting medication again is as follows
Hydrolysising protease 0.2g, chymotrypsin 0.1g, Cefoxitin 0.1g, Edaravone 0.1g, compound injection of red sage root
0.2ml。
2nd, prepare
1st, the preparation of office's injection thing
Cacaine, prednisolone, the vitamin B1 extracted respectively according to quantity, makes it be mixed into anesthetic；
2nd, the preparation of injection thing again
Hydrolysising protease, chymotrypsin, Cefoxitin, Edaravone, compound injection of red sage root are extracted according to quantity, make its mixing composition
To treat liquid, every time using 0.2ml.
3rd, the application method of medicine
1st, mastoid process cave is taken, anesthetic is injected in acupuncture point, strict aseptic technique, implements local anaesthesia；
2nd, it is placed in using negative-pressure cup on mastoid process acupuncture point, 0.1kp vacuum suction 3-4 minutes；
3rd, treatment liquid 0.2ml is extracted with puncture needle, injection treatment liquid in sclerotin is pierced into by mastoid process acupuncture point, then with adhesive bandage sealing label
Pinprick.
Drug hydrolysis protease of the present invention is antiseptic, has antiviral function；Chymotrypsin can promote blood block, purulence
The digestion of sexual secretion and slough is removed；Cefoxitin has stronger antibacterial functions；Edaravone is a kind of protective agent,
Free radical, anti-lipid peroxidation, so as to suppress the oxidative damage of vascular endothelial cell, nerve cell can be removed；Compound
The red sage root has Stasis through, the function of the promoting flow of qi and blood circulation, and the present invention combines said medicine so that each efficacy of drugs produces collaboration and made
With so as to effectively treat tinnitus.
Beneficial effects of the present invention are expanded on further with reference to test example.
[test example] accepts the people of tinnitus patient 36 for medical treatment, is injected and used to patient with above-mentioned application method, as a result shown, recovery from illness 34
People, 2 people recover, total effective rate 100%.
Claims (3)
1. a kind of medicine for treating tinnitus, including office note medication and note medication again, it is characterised in that：It is by following dosage respectively
Medicine made of：
（1）The dosage of office's note medication is as follows
Cacaine 2ml, prednisolone 0.1g, vitamin B1 0.1g；
（2）The dosage for noting medication again is as follows
Hydrolysising protease 0.2g, chymotrypsin 0.1g, Cefoxitin 0.1g, Edaravone 0.1g, compound injection of red sage root
0.2ml。
A kind of 2. preparation method for treating tinnitus medicine, it is characterised in that：It comprises the following steps：
（1）The preparation of office's injection thing
Cacaine, prednisolone, the vitamin B1 extracted respectively according to quantity, makes it be mixed into anesthetic；
（2）The preparation of injection thing again
Hydrolysising protease, chymotrypsin, Cefoxitin, Edaravone, compound injection of red sage root are extracted according to quantity, make its mixing composition
To treat liquid, every time using 0.2ml.
A kind of 3. application method for treating tinnitus medicine, it is characterised in that：Application method is as follows：
（1）Mastoid process cave is taken, anesthetic is injected in acupuncture point, strict aseptic technique, implements local anaesthesia；
（2）It is placed in using negative-pressure cup on mastoid process acupuncture point, 0.1kp vacuum suction 3-4 minutes；
（3）Treatment liquid 0.2ml is extracted with puncture needle, injection treatment liquid in sclerotin is pierced into by mastoid process acupuncture point, then sealed with adhesive bandage
Paste pinprick.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711340568.8A CN107823636A (en) | 2017-12-14 | 2017-12-14 | A kind of medicine for treating tinnitus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711340568.8A CN107823636A (en) | 2017-12-14 | 2017-12-14 | A kind of medicine for treating tinnitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107823636A true CN107823636A (en) | 2018-03-23 |
Family
ID=61644358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711340568.8A Withdrawn CN107823636A (en) | 2017-12-14 | 2017-12-14 | A kind of medicine for treating tinnitus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107823636A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102026623A (en) * | 2008-05-14 | 2011-04-20 | 奥德纳米有限公司 | Controlled-release corticosteroid compositions and methods for treating otic disorders |
| CN102240357A (en) * | 2011-08-15 | 2011-11-16 | 江苏苏南药业实业有限公司 | Medicament for treating tinnitus and preparation method thereof |
| CN104435374A (en) * | 2014-12-29 | 2015-03-25 | 黑龙江中医药大学 | Acupoint injection for treating subjective tinnitus and preparation method of acupoint injection |
| CN106474153A (en) * | 2015-08-27 | 2017-03-08 | 沈敏辅 | Prevention or treatment phonosensitive nerve deafness or tinnitus include the pharmaceutical composition rich in hematoblastic blood plasma and its using method |
-
2017
- 2017-12-14 CN CN201711340568.8A patent/CN107823636A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102026623A (en) * | 2008-05-14 | 2011-04-20 | 奥德纳米有限公司 | Controlled-release corticosteroid compositions and methods for treating otic disorders |
| CN102240357A (en) * | 2011-08-15 | 2011-11-16 | 江苏苏南药业实业有限公司 | Medicament for treating tinnitus and preparation method thereof |
| CN104435374A (en) * | 2014-12-29 | 2015-03-25 | 黑龙江中医药大学 | Acupoint injection for treating subjective tinnitus and preparation method of acupoint injection |
| CN106474153A (en) * | 2015-08-27 | 2017-03-08 | 沈敏辅 | Prevention or treatment phonosensitive nerve deafness or tinnitus include the pharmaceutical composition rich in hematoblastic blood plasma and its using method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ramadhinara et al. | Use of wireless microcurrent stimulation for the treatment of diabetes-related wounds: 2 case reports | |
| US20100310654A1 (en) | Homeopathic remedies for use before and after aesthetic injectable and surgical procedures to minimize swelling and bruising | |
| CN107823636A (en) | A kind of medicine for treating tinnitus | |
| CN101890180A (en) | Wound dressing | |
| CN103479817A (en) | Wound healing gel | |
| CN105434467A (en) | Chilblain therapeutic agent and production method thereof | |
| CN203400332U (en) | Bromhidrosis-resistance silver fiber medicinal patch | |
| CN107469058A (en) | A kind of abdominal pain and distension patch | |
| CN1969992A (en) | Pharmaceutical composition for treating acne and application method thereof | |
| CN203042644U (en) | Aloe wound paste | |
| CN104027391A (en) | Traditional Chinese medicine lotion for treating sweat stains | |
| Berard | Acute surgical wounds managed with minimally adherent silver dressings during 2016-2017: A pilot study | |
| CN203107744U (en) | Bactericide patch | |
| RU2286761C1 (en) | Method for treating neurosensory impaired hearing | |
| RU2674445C1 (en) | Alcohol spray for external use | |
| Ollar | Physicians Take Heed of the Potential for the Appearance of Opportunistic Mycotic Infections in COVID-19 and Lyme Disease | |
| CN107096094A (en) | A kind of delay pin with function promoting blood circulation and removing blood stasis fixes adhesive plaster | |
| CN106551996A (en) | A kind of medicine for treating tinea pedis | |
| CN204840551U (en) | Evaporation type inbalation administration device | |
| CN1152714C (en) | A kind of film-replenishing ear drops medicinal preparation | |
| CN105381309A (en) | Medicine for treating dental ulcers and preparing method thereof | |
| CN106581034A (en) | Drug used for treating rot of mouth and surrounding skin thereof caused by viruses | |
| CN104739915A (en) | Minor prescription for treating whitlow | |
| WO2016037388A1 (en) | Preparation for promoting wound healing and preparation method and usage method thereof | |
| CN104257777A (en) | Traditional Chinese medicine composition for treating rhinitis, nasosinusitis and frontal sinusitis and preparation method of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180323 |
|
| WW01 | Invention patent application withdrawn after publication |